کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
10895779 1083486 2014 8 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Acute promyelocytic leukemia: What is the new standard of care?
ترجمه فارسی عنوان
لوسمی پرومیلوسیتیک حاد: استاندارد جدید مراقبت چیست؟
موضوعات مرتبط
علوم زیستی و بیوفناوری بیوشیمی، ژنتیک و زیست شناسی مولکولی تحقیقات سرطان
چکیده انگلیسی
Acute promyelocytic leukemia (APL) is one of the most exciting stories of modern medicine. Once a disease that was highly lethal, the majority of patients are now cured with the advent of molecularly targeted therapy with all-trans retinoic acid (ATRA) and arsenic trioxide (ATO). In many patients, chemotherapy can be omitted completely, particularly in patients with low- or intermediate-risk disease (white blood cell count ≤ 10,000/μl). Recent data show overall survival exceeding 90% with ATRA and ATO-based induction and consolidation strategies. In the uncommon patient in whom relapse does occur, most can still be cured with ATO and autologous hematopoietic cell transplantation. Remaining challenges in APL management include the rapid identification and treatment of newly diagnosed patients to decrease the early death rate, optimizing treatment strategies in high-risk patients (white blood cell count > 10,000/μl), and the role of maintenance therapy in lower risk patients.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Blood Reviews - Volume 28, Issue 5, September 2014, Pages 205-212
نویسندگان
, ,